SCHEMBL4342202

SCHEMBL4342202

COc1ccc(-c2noc(N)c2-c2ccncc2)c(F)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 4/20 0.53
HSP90AA1 P07900 1/20 0.52
MLYCD O95822 2/20 0.46
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
TP53 P04637 1/20 0.42
HPGD P15428 1/20 0.42
HTT P42858 1/20 0.42
SRC P12931 1/20 0.41
BRAF P15056 1/20 0.41
KDR P35968 1/20 0.41
MAPK11 Q15759 2/20 0.40
ADORA2A P29274 1/20 0.40
MAPK13 O15264 1/20 0.40
MAPK12 P53778 1/20 0.40
MAPK9 P45984 1/20 0.38
MAPK10 P53779 1/20 0.38
USP7 Q93009 1/20 0.38
TEK Q02763 1/20 0.38
PTGS2 P35354 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1874828 0.85 MAPK14 (0.55) MAPK14HSP90AA1MLYCDNPC1RAB9A
SCHEMBL4339480 0.81 MAPK14 (0.57) MAPK14HSP90AA1MLYCDRAB9AHPGD
SCHEMBL4337249 0.80 MAPK14 (0.67) MAPK14HSP90AA1MLYCDNPC1RAB9A
SCHEMBL4332772 0.80 MAPK14 (0.62) MAPK14HSP90AA1MLYCDNPC1RAB9A
SCHEMBL4341519 0.79 MLYCD (0.56) MAPK14MLYCDNPC1RAB9ASRC
SCHEMBL27744977 0.79 TP53 (0.60) MAPK14HSP90AA1MLYCDNPC1RAB9A
SCHEMBL4335175 0.77 MAPK14 (0.61) MAPK14HSP90AA1MLYCDNPC1RAB9A
SCHEMBL4335625 0.77 MAPK14 (0.61) MAPK14HSP90AA1MLYCDNPC1SRC
SCHEMBL4335463 0.76 MAPK14 (0.57) MAPK14HSP90AA1MLYCDNPC1RAB9A
SCHEMBL4480878 0.74 MAPK14 (0.55) MAPK14HSP90AA1MLYCDNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207203-B2 Pyridylisoxazole derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-06-26 US disclosed
US-20090306145-A1 Pyridylisoxazole Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2036905-A1 PYRIDYLISOXAZOLE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2009-03-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306145-A1 Pyridylisoxazole Derivatives CNKSR1, MAPK1, MAPK3 MAPK14 43/4885HSP90AA1 2550/4885MLYCD 4475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.